In patients with platinum-resistant ovarian cancer, however, targeting a specific cytokine/chemokine (e.g., monoclonal antibodies against IL-6 or TNF-α) has only shown a transient and limited antitumor effect. This evidence concerns the gene IL6 and ovarian cancer.